SignalXSignalX

Cencora (COR) Q4 2025 10-Q Quarterly Report

Filed: Feb 4, 2026Period ending Dec 31, 2025
Consumer Staples
Wholesale-Drugs, Proprietaries & Druggists' SundriesSEC EDGAR
Cencora Overview

Cencora (COR) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 4, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Cencora Q4 2025 10-Q Analysis

Management Discussion & Analysis

  • • Revenue $85.9B, up 5.5% YoY (+$4.4B); U.S. Healthcare Solutions +5.0% ($3.7B), International Healthcare Solutions +9.6% ($0.7B)
  • • Gross profit $3.07B, up 20.1% YoY; U.S. Healthcare Solutions margin 2.47% (+46 bps), International Healthcare Solutions +3.3% gross profit increase
  • • Operating income $760M, up 7.7%; U.S. Healthcare Solutions +21.0%, margin 1.09% (+14 bps); International Healthcare Solutions down 13.9%
  • • Operating cash flow used $2.3B vs $2.7B prior year; capital expenditures $119M vs $106M; $4.6B OneOncology acquisition funded by new debt
  • • Management highlights strategic business reorganization, OneOncology acquisition integration, expects $900M capex in fiscal 2026, notes opioid litigation payments over 13 years totaling $4.3B

Risk Factors

  • • No material changes in risk factors compared to 10-K for fiscal year ended September 30, 2025
  • • Carried-forward regulatory risk: potential impact of evolving healthcare laws on pricing and reimbursement policies
  • • Carried-forward market risk: intense competition affecting market share in pharmaceuticals distribution
  • • Carried-forward liquidity risk: exposure to short-term debt maturities requiring ongoing cash flow management

Cencora Q4 2025 Quarterly Financials
XBRL

Revenue

$85.9B

▲ +5.5% YoY

Net Income

$560M

▲ +14.5% YoY

Gross Margin

3.6%

▲ +44bp YoY

Operating Margin

0.9%

▲ +2bp YoY

Net Margin

0.7%

▲ +5bp YoY

ROE

29.3%

▼ -18631bp YoY

Total Assets

$78.4B

▲ +13.5% YoY

EPS (Diluted)

$2.87

▲ +14.8% YoY

Operating Cash Flow

-$2.3B

▲ +15.2% YoY

Source: XBRL data from Cencora Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Cencora

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.